Supratentorial meningioma

Summary

Supratentorial meningioma (MONDO:0850303) is a disease and 1 clinical trial. Top therapeutic interventions include bevacizumab. A subtype of meningioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	supratentorial meningioma
Mondo ID	MONDO:0850303
DOID	DOID:0080843
NCIT	C7048
UMLS	C1336537
MedGen	234913
GARD	0026600
Is cancer (heuristic)	no

Disease family

This is a subtype of meningioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › central nervous system neoplasm › tumor of meninges › meningioma › supratentorial meningioma

Related subtypes (36): intraspinal meningioma, intraventricular meningioma, intraorbital meningioma, clear cell meningioma, posterior cranial fossa meningioma, anterior cranial fossa meningioma, skull base meningioma, benign meningioma, secretory meningioma, lymphoplasmacyte-rich meningioma, pediatric meningioma, microcystic meningioma, middle cranial fossa meningioma, rhabdoid meningioma, optic nerve sheath meningioma, lung meningioma, malignant leptomeningeal tumor, jugular foramen meningioma, angiomatous meningioma, psammomatous meningioma, fibrous meningioma, meningothelial meningioma, transitional meningioma, petrous apex meningioma, gasserian ganglion meningioma, skin meningioma, periocular meningioma, pineal region meningioma, parapharyngeal meningioma, radiation-induced meningioma, familial meningioma, grade III meningioma, papillary meningioma, optic tract meningioma, grade II meningioma, intracranial meningioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02847559	PHASE2	RECRUITING	Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1